Liquid Biopsy Market To Reach USD 5.96 Billion By 2030: Grand View Research, Inc.
Global liquid biopsies market is anticipated to reach 5,958.3
million by 2030, according to a new report by Grand View Research, Inc. As
these less invasive biopsies are able to address a number of significant
challenges associated with conventional biopsies such as, high level of invasiveness,
incompleteness of cancer information that is acquired, associated post-biopsy
serious medical complications, and subsequent cost inclusions. A growing need
for more advanced, efficient and accurate method which provides a holistic view
of the tumor and metastasis is the prime factor fueling rapid development of
liquid biopsies.
The market has gained considerable traction in the past
couple of years. A number of clinical research projects related to circulating
tumor cells, and cell-free tumor DNA have been initiated in the latter half of
the past decade. As a result, there are a number of ongoing clinical trials
that are due to be completed between post 2017-18. It is expected that upon
successful completion, commercialization of these assays and tests will provide
the market a significant boost in potential addressable target revenue and fuel
growth through to 2030.
Browse full research report on Liquid Biopsy Market: http://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Further key findings from the report suggest:
- In
terms of applications, therapy selection of metastatic cancers is the key
area of liquid biopsy usage as these provide significant insights into the
unique genetic information encoded in CTCs and ctDNAs. Furthermore, with
the addition of more research data reinforcing the usage of liquid
biopsies over the coming years, it is expected that their application for
molecular monitoring of diseases will also be a lucrative source of
revenue through to 2030
- Key
biomarkers that any liquid biopsy targets include circulating tumor cells,
circulating tumor DNA and exosomes that are macrovesicles containing tumor
RNA, or tumor protein freely circulating in the patient’s bloodstream.
Assays for ctDNA are expected to account for the largest share of revenue
through to 2030 owing to the currently present assays and expected number
of products that are to be commercialized over the coming decade.
- Development
of parallel multi-gene analysis using next generation sequencing
technology is the underlying factor that has enabled oncologists to more
efficiently sequence ctDNA and gain insights related to cancer metastasis
and the related mechanism. This understanding provides a patient-centric
systemic view of cancer and aids in its long term monitoring.
- North
America, specifically the U.S. accounts for the largest share of revenue
for the development of liquid biopsy market. The region was observed to
account for around 50% of the global potential in 2015 owing to the high
number clinical development projects underway for the commercialization of
CTC and ctDNA assays till 2020. Furthermore, throughout the forecast
period, U.S. is expected to dominate revenue generation owing to the
dynamic nature & being the region of prime activity, research and
development with respect to liquid biopsy and next generation sequencing
technology.
- Although,
post successful commercialization through to 2030, Asia Pacific is
expected to be a lucrative region for development as it is expected to be
characterized by the presence of a large patient population base,
developing healthcare framework and growth in integration of more advanced
healthcare practices.
- The
market is in its developing phase and is characterized by the presence of
a number of relatively smaller entities involved in innovation and new
product development. Companies such as Biocept, Adaptive Biotechnologies,
NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome
Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating
in the space and have a number of commercialized assays in their
portfolios for liquid biopsy.
- Furthermore,
as this space has a high lucrative potential, and is considerably
influenced by the developments in NGS technology, there are a number of
major players that have ongoing investigational & observational
clinical trials and are due to be completed by 2017 to 2019. Collectively,
over 30 clinical trials are currently registered as active by companies
including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom,
LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone.
Anticipated successful commercialization of these products is expected to
fuel growth over the forecast period.
Grand View Research has segmented the liquid biopsy market
on the basis of application, sample type, biomarker, technology, and region:
Global Liquid Biopsy Outlook, by Application (Revenue,
USD Million, 2013 - 2030)
- Therapy
Selection for Metastatic Breast Cancer (MBS)
- Therapy
Selection for Other Metastatic Cancer
- Molecular
Health Monitoring
Global Liquid Biopsy, by Sample Type (Revenue, USD
Million, 2013 - 2030)
- Blood
Sample based
- Urine
Sample based
- Other
Bio Fluids (Tissue fluids and Saliva) based
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
- Circulating
Tumor Cells (CTC)
- Circulating
Tumor DNA (ctDNA)
- Exosomes
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
- Multi
- gene - parallel Analysis (NGS)
- Single
Gene Analysis (PCR Microarrays)
Global Liquid Biopsy Market, Regional Outlook (Revenue,
USD Million, 2013 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Brazil
- MEA
- South
Africa
Access press release of this research
report by Grand View Research: http://www.grandviewresearch.com/press-release/liquid-biopsy-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
For more information:
www.grandviewresearch.com
Comments
Post a Comment